Helio Genomics has announced that its ‘sister company’ Laboratory for Advanced Medicine & Health Group (LAMH) has achieved a significant milestone with the National Medical Product Administration (NMPA)’s first-ever approval for a liver cancer-related liquid biopsy test in China. This approval marks a breakthrough in non-invasive diagnostic testing for liver cancer in the region.
LAMH’s Liver Cancer Detection Test: A Tailored Approach for Asia-Pacific Populations
LAMH’s product is a variant of Helio’s HelioLiver test, developed by the same core scientific team and specifically recalibrated to address the unique genetic profile of Asia-Pacific populations. The test leverages Helio’s intellectual property and employs a multi-analyte blood test that assesses cell-free DNA (cfDNA) methylation patterns, serum protein markers, and demographic information to detect hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. Given that China bears the world’s highest burden of liver cancer and HCC, largely due to widespread hepatitis B infections, this test has the potential to significantly impact early detection and treatment strategies.
Collaboration and Integration in China
To ensure the seamless integration and broad reach of their innovative product, LAMH plans to collaborate with leading medical institutions, healthcare providers, and key stakeholders across China. This partnership approach will facilitate the adoption of the test and enhance its accessibility to patients in need.-Fineline Info & Tech
